Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...
While younger generations navigate life getting premium services at zero cost, many of us are unknowingly hemorrhaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback